(MENAFN- GlobeNewsWire - Nasdaq) The report "Catalyst Monitor Q4 2025" highlights upcoming market opportunities in biotech and pharma, focusing on key approvals and trials such as Cytokinetics's aficamten, Aldeyra's reproxalap, and GSK's depemokimab. It provides insights into potential market-moving events and competitive positioning for new therapies.

Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The "Catalyst Monitor: Q4 2025 Outlook" report has been added to ResearchAndMarkets's offering.
This report compiles published, predictive intelligence based on interviews with key opinion leaders (KOLs) on market-moving events that are expected to occur in Q4 2025.

The report delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, top-line results, regulatory filings, PDUFA dates, and expected approvals. The report covers 20 significant catalyst events that are expected to occur in Q4 2025.
Some of the catalysts covered in the report, include approval decisions for Cytokinetics's aficamten for obstructive hypertrophic cardiomyopathy, Aldeyra's reproxalap for keratoconjunctivitis sicca, GSK's depemokimab for chronic rhinosinusitis and asthma, and more.
Additionally, experts also discuss the ongoing clinical trials with Quoin Pharmaceuticals' QRX-003 for Netherton syndrome, Cogent Biosciences's bezuclastinib for systemic mastocytosis, Sanofi's tolebrutinib for Primary progressive multiple sclerosis (PPMS), and more.
Scope

• The Q4 Catalyst Monitor report offers exclusive forward-looking insights on Phase II and Phase III results, regulatory drug approvals and more, based on exhaustive research and exclusive KOL interviews.

Reasons to Buy

• Which biopharma companies are expecting major milestones such as FDA decisions or late-stage trial completions and results in Q4 2025?
• Which upcoming regulatory catalysts that are expected in Q4 2025 are likely to be market-moving events?
• How do the number of expected regulatory events like trial initiations and trial completions in Q4 compare to the previous quarter?
• Which are the top therapy areas for market-moving catalysts in Q4 compared to the previous quarter?
• Which companies have the highest numbers of upcoming catalysts expected in Q4?
• What commercial impact could GSK's depemokimab have in the asthma therapeutics market if approved, based on Phase III data?
• What is the commercial and clinical significance of Cogent Biosciences' upcoming Phase III trial readout for bezuclastinib in systemic mastocytosis, and how might it compete with the existing therapeutic option?
• How do KOLs assess the clinical and commercial prospects of DBV's DBV-712 as a treatment for peanut allergies given its past regulatory history?
• What are expert views on Pfizer's Adcetris and how it may compete in the Diffuse Large B-cell Lymphoma (DLBCL) space?

Key Topics Covered:

• About the Analyst
• Quarterly Catalyst Comparisons
• Catalyst Calendar
• Catalysts
• Appendix

Companies Featured

• OrsoBio
• Edgewise Therapeutics
• Galimedix Therapeutics
• DBV Technologies
• Pfizer
• Georgiamune
• South Rampart Pharma
• GSK
• Aldeyra Therapeutics
• Cytokinetics
• Novo Nordisk
• Quoin Pharmaceuticals
• Insmed
• AstraZeneca
• Daiichi Sankyo
• Cogent Biosciences
• Sanofi
• Xenon Pharmaceuticals

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN31102025004107003653ID1110275241